TTFields

Only TTFields therapy harnesses the versatile power of electric fields to outsmart solid tumors

IN YOUR FIGHT AGAINST CANCER, MAKE YOUR NEXT MOVE ELECTRIC

TTFields targeting cancer cells without significantly affecting healthy cells

Versatile
Modality

With a poor survival outlook, physicians and patients need additional solid tumor treatment strategies that utilize innovative modalities.1-3

Discover the innovation of TTFields therapy

What is TTfields therapy?
TTFields have multiple mechanisms of action that work together
to physically disrupt tumor cells

Multimechanistic
Action

TTFields therapy is clinically versatile, rooted in its multifaceted effect on cancer cells.4-6

Explore how its multiple mechanisms each work to disrupt tumor progression

How does it work?
Investigations ongoing in clinical and preclinical trials

Expanding
Treatment Possibilities

TTFields have been extensively researched, with preclinical data demonstrating enhanced effects when used with other cancer treatments.4, 7-12

See its many potential applications

See the possibilities

As a cutting-edge technology, TTFields are the subject of ongoing investigations in multiple tumor types.7-12

Learn how you can educate colleagues on TTFields therapy with our specially designed slide kit as well as educational videos.

EXPLORE RESOURCES
As a cutting-edge technology, TTFields are the subject of ongoing investigations in multiple tumor types
Contact Novocure for more information on TTFields therapy

More questions about TTFields therapy?

Contact US

References: 1. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94. doi:10.1038/nrclinonc.2017.166 2. Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286-301. doi:10.1038/nrc.2017.17 3. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14(1):57-66. doi:10.1038/nrclinonc.2016.96 4. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984 5. Voloshin T, Schneiderman RS, Volodin A, et al. Tumor treating fields (TTFields) hinder cancer cell motility through regulation of microtubule and actin dynamics. Cancers (Basel). 2020;12(10):1-18. doi:10.3390/cancers12103016 6. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. 2009;28(1-2):5-14. doi:10.1007/s10555-008-9166-3 7. Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81(3):445-450. doi:10.1016/j.lungcan.2013.06.025 8. Novocure. Pivotal, open-label, randomized study of radiosurgery with or without tumor treating fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC). Clinical Trials. Accessed June 21, 2022. https://clinicaltrials.gov/ct2/show/NCT02831959 9. Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Küng M. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology. 2019;19(1):64-72. doi:10.1016/j.pan.2018.10.004 10. Novocure. Effect of tumor treating fields (TTFields, 150 kHz) as front-line treatment of locally-advanced pancreatic adenocarcinoma concomitant with gemcitabine and nab-paclitaxel (PANOVA-3). Clinical Trials. Accessed June 21, 2022. https://clinicaltrials.gov/ct2/show/NCT03377491 11. Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study. Gynecol Oncol. 2018;150(3):471-477. doi:10.1016/j.ygyno.2018.07.018 12. Novocure. Effect of tumor treating fields (TTFields, 200 kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3). Clinical Trials. Accessed June 21, 2022. https://clinicaltrials.gov/ct2/show/NCT03940196